Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.
We examined the safety and immunogenicity of a human leukocyte antigen-based HIV envelope polyvalent synthetic peptide vaccine, C4-V3, alone and in combination with subcutaneous IL-12 in nine HIV-infected patients. Lymphocyte proliferative responses increased threefold or more to all four peptides at two consecutive post-immunization timepoints for four individuals. Three responders had received IL-12, suggesting a possible adjuvant effect of Il-12. Transient mild injection site reactions (7.9) and systemic symptoms (3/9) occurred.
Sha
Beverly E
BE
Department of Medicine, Section of Infectious Diseases, Rush Medical College, Chicago, IL, USA.
Onorato
Michelle
M
Bartlett
John A
JA
Bosch
Ronald J
RJ
Aga
Evgenia
E
Nokta
Mostafa
M
Adams
Elizabeth M
EM
Li
Xiao-Dong
XD
Eldridge
John
J
Pollard
Richard B
RB
D016915:AIDS Vaccines / Q000009:adverse effects / Q000276:immunology*; D000276:Adjuvants, Immunologic; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007271:Injections, Intradermal; D018664:Interleukin-12 / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D006680:HLA Antigens; D014614:Vaccines, Synthetic; D018664:Interleukin-12